ALCJ.PA Crossject EURONEXT €2.20 (+9.18%) 23 Mar ahead of earnings: what to watch

ALCJ.PA stock jumped intraday on 23 Mar after volumes spiked and the share hit €2.20, a +9.18% move from the prior close. Crossject SA (ALCJ.PA) trades on EURONEXT in Europe and is due to report on 25 Mar 2026. Investors should watch guidance, clinical milestones for the ZENEO platform, and cash-flow signals. We use financial metrics and analyst context to frame potential reactions ahead of earnings.

ALCJ.PA stock: intraday price action and volume

Crossject (ALCJ.PA) trades at €2.20 with a day low of €2.04 and a high of €2.21. Volume reached 309,268 shares, above the average volume of 265,999, signalling increased trader interest. The stock is up 9.18% intraday, driven by positioning ahead of the 25 Mar earnings release.

Earnings calendar and near-term catalysts

The company reports on 25 Mar 2026, two days from today. Market attention will focus on revenue recognition, clinical program updates for ZENEO, and cash runway commentary. Regulatory or partnership news could swing the stock given Crossject’s development-stage profile and limited revenue base.

ALCJ.PA stock earnings preview: metrics to watch

Key items for the report include cash balance, R&D spend, and any revenue guidance. Crossject shows EPS -€0.22 and a trailing PE of -9.68, reflecting losses. Analysts will also weigh clinical milestones and manufacturing capacity statements that affect medium-term commercial rollouts.

Meyka AI rates ALCJ.PA with a score out of 100

Meyka AI rates ALCJ.PA with a score out of 100: 69.47 (Grade B), suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational only and are not financial advice.

Valuation, technicals and price targets

Fundamentals show a market cap of €111.82M, price averages: 50-day €2.05, 200-day €1.97. The EPS is -€0.22 and PE is -9.68. Technically RSI sits at 55.59 and Bollinger upper band is €2.22, indicating balanced momentum. Reasonable price targets: bear €1.20, base €2.50, bull €3.50, reflecting clinical binary risk and small-cap volatility.

Risks, sector context and opportunities

Crossject operates in Europe’s Healthcare sector, which is down 6.66% YTD, increasing relative risk for small-cap developers. Key risks include trial setbacks, cash burn, and regulatory delay. Opportunities include successful ZENEO approvals, partner deals, or upside from new indications. Expect high volatility and low liquidity around news.

Final Thoughts

Key takeaways: ALCJ.PA stock trades at €2.20 on EURONEXT with intraday strength and above-average volume ahead of the 25 Mar 2026 earnings release. Fundamentals show losses with EPS -€0.22 and a negative PE, so the report must clarify cash and milestones. Meyka AI’s forecast model projects a yearly target of €1.28, implying an estimated -42.01% downside versus the current price of €2.20. Forecasts are model-based projections and not guarantees. Traders should weigh the Meyka grade (B, HOLD), the upcoming clinical and cash signals, and prepare for binary reactions. For live quotes and filings, see Bloomberg coverage and market summaries on Investing.com. For our platform view, visit the Crossject page on Meyka AI: https://meyka.ai/stocks/ALCJ.PA

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.